- Earth Science Tech has uplisted to the OTCQB Venture Market, a premier public market that provides investors with a trusted trading environment
- The uplisting is one of several milestones the company has reported during the current financial year 2027, which began on April 1, 2026
- The company reported its Q1 2027 financial results, marking a 3% growth in revenue with a 57% increase in net income
- The company also acquired Meduvo LLC and Zoolzy and held its annual meeting of shareholders
Earth Science Tech (OTCQB: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, successfully uplisted to the OTCQB Venture Market effective September 17, 2026. The listing on OTCQB, an established public market for growth-stage and entrepreneurial companies, means ETST has met rigorous financial and reporting standards, undergone a verification process, and complied with strict management certification requirements (https://ibn.fm/0TQ91).
The uplisting is the latest milestone in fiscal year 2027, which began on April 1, 2026. During the intervening period, the company reported its Q1 2027 financial results, acquired Meduvo LLC (a compounding pharmacy) and Zoolzy LLC, and held its annual meeting of shareholders.
The Q1 results reflected steady compounding progress and the inherent operating leverage within ETST’s business model: revenue grew 3% to $9.0 million, gross profit rose 3.1% to $6.3 million, and net income jumped 57% to $715,697, with all key operating subsidiaries remaining profitable (https://ibn.fm/V8OXi).
According to Giorgio R. Saumat, CEO and Chairman of the Board, the company maintained internal standards and continues to actively focus on driving even greater operational efficiencies. These standards are also evident externally, especially with the recent uplisting to the OTCQB market, which emphasizes elevated transparency and aims to provide investors with a trusted trading environment.
Moreover, ETST acquired Zoolzy, a wholesale distributor of active pharmaceutical ingredients (“APIs”) and finished FDA-approved prescription products (https://ibn.fm/VILA1). In his address at the Annual Meeting, Mr. Saumat said the acquisition represented the company’s move “to unlock a whole new business”: the lucrative animal health market.
Zoolzy creates a new supply line that supports the formulation of unique, flavored, and easy-to-administer veterinary therapeutics. It also enables Earth Science Tech and its network of compounding pharmacies to acquire APIs for human medication; they will be able to secure raw materials as well as new, highly sought-after APIs at competitive wholesale prices that increase profit margins.
The company also held its Annual Meeting of Stockholders on August 31, 2026. During the meeting, shareholders authorized the Board to pursue a reverse stock split, if deemed necessary, to support plans to uplist to Nasdaq or NYSE. The stockholders also ratified a plan to retire the current dual-class voting structure by negotiating the sale of Series B Preferred Stock, with the execution of this proposal aiming to attract institutional capital. Moreover, the shareholders approved the appointment of an independent registered public accounting firm, the re-election of seven director nominees, and a new non-dilutive executive compensation framework. Mr. Saumat and management also fielded questions (https://ibn.fm/C8zGp).
The milestones reported so far represent the company’s relentless focus on maximizing shareholder value. The company remains committed to optimizing the operational frameworks of its holdings to support scalable, sustainable expansion.
For more information, visit the company’s website at www.EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
